MA49589A - Composition pharmaceutique permettant d'améliorer les niveaux de fer dans le sang, comprenant du polymaltose de fer (iii) et une autre substance active adaptée à l'absorption du fer choisie parmi le folinate de calcium pentahydraté, la vitamine c ou une combinaison des deux - Google Patents
Composition pharmaceutique permettant d'améliorer les niveaux de fer dans le sang, comprenant du polymaltose de fer (iii) et une autre substance active adaptée à l'absorption du fer choisie parmi le folinate de calcium pentahydraté, la vitamine c ou une combinaison des deuxInfo
- Publication number
- MA49589A MA49589A MA049589A MA49589A MA49589A MA 49589 A MA49589 A MA 49589A MA 049589 A MA049589 A MA 049589A MA 49589 A MA49589 A MA 49589A MA 49589 A MA49589 A MA 49589A
- Authority
- MA
- Morocco
- Prior art keywords
- iron
- polymaltose
- vitamin
- blood
- chosen
- Prior art date
Links
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 title 4
- 229910052742 iron Inorganic materials 0.000 title 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 title 1
- -1 CALCIUM FOLINATE PENTAHYDRATE Chemical class 0.000 title 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 title 1
- 238000010521 absorption reaction Methods 0.000 title 1
- 239000013543 active substance Substances 0.000 title 1
- 239000008280 blood Substances 0.000 title 1
- 210000004369 blood Anatomy 0.000 title 1
- 235000008207 calcium folinate Nutrition 0.000 title 1
- 239000011687 calcium folinate Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/295—Iron group metal compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GR20180100160A GR1009597B (el) | 2018-04-16 | 2018-04-16 | Φαρμακευτικο σκευασμα για την ενισχυση των επιπεδων σιδηρου στο αιμα, που περιεχει πολυμαλτοζικο σιδηρο (ιιι) και μια δραστικη ουσια επιλεγμενη απο πενταϋδρικο φυλλινικο ασβεστιο, βιταμινη c ή συνδυασμο των δυο, που ενισχυει την απορροφηση σιδηρου |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA49589A true MA49589A (fr) | 2020-05-20 |
| MA49589B1 MA49589B1 (fr) | 2023-09-27 |
Family
ID=66102021
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA49589A MA49589B1 (fr) | 2018-04-16 | 2019-03-22 | Composition pharmaceutique permettant d'améliorer les niveaux de fer dans le sang, comprenant du polymaltose de fer (iii) et une autre substance active adaptée à l'absorption du fer choisie parmi le folinate de calcium pentahydraté, la vitamine c ou une combinaison des deux |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP3556351B1 (fr) |
| DK (1) | DK3556351T3 (fr) |
| ES (1) | ES2956286T3 (fr) |
| FI (1) | FI3556351T3 (fr) |
| GR (1) | GR1009597B (fr) |
| HR (1) | HRP20231108T1 (fr) |
| HU (1) | HUE063948T2 (fr) |
| LT (1) | LT3556351T (fr) |
| MA (1) | MA49589B1 (fr) |
| PL (1) | PL3556351T3 (fr) |
| PT (1) | PT3556351T (fr) |
| RS (1) | RS64559B1 (fr) |
| SI (1) | SI3556351T1 (fr) |
| SM (1) | SMT202300309T1 (fr) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4931441A (en) * | 1988-11-09 | 1990-06-05 | Luitpold Pharmaceuticals, Inc. | Stabilized aqueous leucovorin calcium compositions |
| IT1237509B (it) * | 1989-10-31 | 1993-06-08 | Magis Farmaceutici | Complessi con le ciclodestrine indicati per il trattamento di tutte leforme anemiche da carenza di folati, loro preparazione e relative composizioni farmaceutiche |
| CN101282735A (zh) * | 2005-10-11 | 2008-10-08 | 拜耳消费者保健股份公司 | 掩蔽金属味道的铁盐和铜盐混合物 |
| EP1790356A1 (fr) * | 2005-11-24 | 2007-05-30 | Vifor (International) Ag | Préparation contenant des complexes de fer(III) et des composés rédoxs |
| ITTO20120506A1 (it) | 2012-06-12 | 2013-12-13 | Inge Spa | Cappuccio per un flacone atto alla conservazione di sostanze da mantenersi separate fino alla loro applicazione. |
| EP2997968A1 (fr) | 2014-09-22 | 2016-03-23 | Ioulia Tseti | Complexes d'hydroxyde de fer (III) avec des sirops de glucose activé et procédé de préparation associé |
-
2018
- 2018-04-16 GR GR20180100160A patent/GR1009597B/el active IP Right Grant
-
2019
- 2019-03-22 ES ES19386016T patent/ES2956286T3/es active Active
- 2019-03-22 SI SI201930621T patent/SI3556351T1/sl unknown
- 2019-03-22 HU HUE19386016A patent/HUE063948T2/hu unknown
- 2019-03-22 RS RS20230778A patent/RS64559B1/sr unknown
- 2019-03-22 PL PL19386016.0T patent/PL3556351T3/pl unknown
- 2019-03-22 HR HRP20231108TT patent/HRP20231108T1/hr unknown
- 2019-03-22 FI FIEP19386016.0T patent/FI3556351T3/fi active
- 2019-03-22 LT LTEP19386016.0T patent/LT3556351T/lt unknown
- 2019-03-22 SM SM20230309T patent/SMT202300309T1/it unknown
- 2019-03-22 MA MA49589A patent/MA49589B1/fr unknown
- 2019-03-22 DK DK19386016.0T patent/DK3556351T3/da active
- 2019-03-22 PT PT193860160T patent/PT3556351T/pt unknown
- 2019-03-22 EP EP19386016.0A patent/EP3556351B1/fr active Active
Also Published As
| Publication number | Publication date |
|---|---|
| SMT202300309T1 (it) | 2023-11-13 |
| LT3556351T (lt) | 2023-09-25 |
| SI3556351T1 (sl) | 2024-02-29 |
| HUE063948T2 (hu) | 2024-02-28 |
| FI3556351T3 (fi) | 2023-10-02 |
| RS64559B1 (sr) | 2023-10-31 |
| MA49589B1 (fr) | 2023-09-27 |
| HRP20231108T1 (hr) | 2023-12-22 |
| EP3556351B1 (fr) | 2023-08-09 |
| DK3556351T3 (da) | 2023-09-18 |
| PL3556351T3 (pl) | 2023-11-27 |
| GR1009597B (el) | 2019-09-16 |
| PT3556351T (pt) | 2023-09-12 |
| ES2956286T3 (es) | 2023-12-18 |
| EP3556351A1 (fr) | 2019-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA51747A (fr) | Formulation d'anticorps pharmaceutique à ph faible | |
| MA46820A (fr) | Composition pharmaceutique comprenant des constructions d'anticorps bi-spécifiques | |
| EP2197858A4 (fr) | Composé de 1,3,5-triazine-2,4,6-triamine ou son sel pharmaceutiquement acceptable, et composition pharmaceutique le comprenant | |
| DE60325379D1 (de) | Zusammensetzung enthaltend 6-Ä3-(1-adamantyl)-4-methoxyphenylÜ-2-naphthanoesäure zur Behandlung dermatologischer Erkrankungen | |
| MA41558B1 (fr) | Compositions d'allergènes mélangés et leurs procédés d'utilisation | |
| MA47425A (fr) | Composition pharmaceutique à faible ph comprenant des constructions d'anticorps d'engagement avec les lymphocytes t | |
| MA44312A (fr) | Anticorps et leurs méthodes d'utilisation | |
| EA200900044A1 (ru) | Замещенные производные 1,3-дифенилпропана, получение и их применение | |
| IL228952A0 (en) | Pharmaceutical compositions comprising ferric citrate for reducing serum phosphate levels, and use thereof for the preparation of medicaments for treating or ameliorating calcium-associated disorders | |
| MD20070267A (en) | Gastroresistant pharmaceutical formulation containing rifaximin | |
| DK1372608T3 (da) | Medicinske aerosolformuleringer | |
| NO20090348L (no) | Substituerte imidazolonderivater, sammensetninger og anvendelser av samme, samt fremgangsmater for fremstilling av samme | |
| BRPI0511616A (pt) | compostos | |
| MX2023009856A (es) | Dosificacion optimizada de diaminofenotiazinas en poblaciones. | |
| EP3498279A4 (fr) | Composition pharmaceutique comprenant comme principes actifs de l'amodiaquine et un médicament anti-diabète, destinée à la prévention ou le traitement du diabète | |
| EP2638910A4 (fr) | Composition comprenant des dérivés de benpropérine en tant que principes actifs pour la prévention et le traitement de maladies associées à l'angiogenèse | |
| MA31941B1 (fr) | Bis-pyridylpyridones en tant qu'antagonistes du récepteur 1 de l'hormone de concentration de la mélanine | |
| CY1117174T1 (el) | ΧΡΗΣΗ 24-norUDCA ΓΙΑ ΤΗΝ ΑΓΩΓΗ ΧΟΛΟΣΤΑΤΙΚΩΝ ΝΟΣΗΜΑΤΩΝ ΤΟΥ ΗΠΑΤΟΣ | |
| ATE341343T1 (de) | Medizinische zusammensetzungen mit diuretischem und die insulinresistenz verbesserndem mittel | |
| MA49589A (fr) | Composition pharmaceutique permettant d'améliorer les niveaux de fer dans le sang, comprenant du polymaltose de fer (iii) et une autre substance active adaptée à l'absorption du fer choisie parmi le folinate de calcium pentahydraté, la vitamine c ou une combinaison des deux | |
| BRPI0608287A2 (pt) | agente endoparasiticida | |
| EP1865954A4 (fr) | Methodes pour eviter un oedeme dans le traitement ou la prevention de maladies sensibles a ppar gamma, telles que le cancer | |
| EP2859897A4 (fr) | Composition pharmaceutique, destinée au traitement de plaies ou à la revitalisation de la peau, comprenant des extraits d'euphorbia kansui, leurs fractions ou des composés diterpéniques séparés des fractions en tant que principe actif | |
| EP2873419A4 (fr) | Composition pharmaceutique comprenant de l'azathioprine en tant que principe actif pour la prévention ou le traitement de tumeurs du cerveau ou de glioblastomes résistants à témodal | |
| EP3624828A4 (fr) | Formulation pharmaceutique comprenant des conjugués d'incrétine-insuline |